CJC-1295: where it stands with the FDA, and what it costs
Usually sold blended with ipamorelin. No FDA-approved drug contains it.
Go to clinicLowest per monthCJC-1295 with ipamorelin injection
Live Vital · $150/mo (supply not stated, counted as 4 weeks: ≈ $161 per 30 days)
Where CJC-1295 stands today
No FDA-approved drug contains CJC-1295 (with or without DAC). FDA placed it in 503A Category 2 in September 2023, citing serious adverse events including increased heart rate and systemic vasodilatory reaction, and removed it in September 2024 after the nominations were withdrawn. On December 4, 2024 the advisory committee voted against listing every form (0-13 for the free base and both DAC forms, 1-12 for the acetate). It is not on the 503A or 503B bulks list, not in any category, and not in HHS's October 2026 interim policy.
For pharmacies compounding one patient's prescription (section 503A)
Not in any 503A category and not on the 503A bulks list. Removed from Category 2 in September 2024 after its nominations were withdrawn; the advisory committee voted against listing every form (Dec 4, 2024); no final rule. Not in HHS's Oct 2026 interim policy.
“Bulk drug substances nominated but withdrawn ... CJC-1295 Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.”
““CJC-1295” has been removed from Category 2 because the nominations were withdrawn by the nominators.”
FDA interim 503A bulks policy: a substance outside Category 1 gets no interim enforcement discretion
“Drug products compounded using a bulk drug substance for which each of the above circumstances are not present are not within the scope of the policy described in this guidance.”
For outsourcing facilities (section 503B)
Not on the 503B bulks list and not in any 503B category (FDA's 503B nominations list, updated March 21, 2025, does not name it)
“Outsourcing facilities, which operate under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), may not compound a drug product that includes a bulk drug substance unless: The bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list), or”
The 503B bulks list holds five substances (diphenylcyclopropenone, glycolic acid, quinacrine HCl oral, squaric acid dibutyl ester, trichloroacetic acid); none of the compounds in this file
“FDA has evaluated the following bulk drug substances and determined that there is a clinical need for outsourcing facilities to compound drug products using these bulk drug substances under section 503B of the FD&C Act:”
The FDA's compounding advisory committee
4 December 2024: Should CJC-1295 (free base), CJC-1295 acetate, CJC-1295 DAC (free base), CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate each be placed on the 503A bulks list?. Vote: Free base 0-13; acetate 1-12; DAC free base 0-13; DAC acetate 0-13; DAC trifluoroacetate 0-13 (yes-no, no abstentions). Committee advised against listing every form; FDA has published no rule since
“VOTE: FDA is proposing that CJC-1295 (free base) NOT be included on the 503A Bulks List. Should CJC-1295 (free base) be placed on the list? Vote Result: Yes: 0 No: 13 Abstain: 0 Committee Discussion: The Committee unanimously agreed that CJC-1295 (free base) should not be included on the 503A Bulks List.”
FDA warnings, recalls and letters
20 June 2025: Recall of CJC-1295 pre-filled syringes. Class II; initiated 2025-05-21, classified 2025-06-20. (Thrive Health and Wellness, LLC dba Thrive Health Solutions, Englewood, CO).
“CJC-1295 Injectable, 6mg/15mg, pre-filled syringe ... Lack of Assurance of Sterility”
For athletes who are tested
Prohibited at all times (in and out of competition) (World Anti-Doping Agency, 2026 Prohibited List (in force 1 Jan 2026; WADA approved a 2027 list in Sept 2026, effective 1 Jan 2027, not read here)).
“growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)”
Our reading
There is no current route to lawful 503A or 503B compounding of CJC-1295 in either form. 'CJC-1295 without DAC' sold as 'Mod GRF 1-29' is covered by the same FDA review.
Every source above was checked again on 14 November 2026.
What 22 clinics charge
- Live VitalCJC-1295 with ipamorelin injection$150/mosupply not stated, counted as 4 weeks: ≈ $161 per 30 days
- FrontCareCJC-1295 with ipamorelin injection$219/mo
- Bodybuilding Health+CJC-1295 with ipamorelin injection (1.5mg)$224/mo
- Andrew MedsCJC-1295 with ipamorelin injection$219/mosupply not stated, counted as 4 weeks: ≈ $235 per 30 days
- Zepym HealthCJC-1295 with ipamorelin injection (1.2mg)$229/mo≈ $245 per 30 days with its fees
What CJC-1295 is
- What it is
- Growth hormone-releasing hormone (GHRH) analog
- How it works
- A modified form of the first 29 amino acids of GHRH; the version with DAC binds to albumin so it lasts longer in the blood.
- How it is given
- Subcutaneous injection
- Also called
- CJC-1295 with DAC, CJC-1295 without DAC, modified GRF 1-29, Mod GRF 1-29
CJC-1295 side by side
About CJC-1295
Is CJC-1295 FDA-approved?
No. No FDA-approved drug contains CJC-1295. What clinics sell is compounded by a pharmacy for a prescription, and the FDA does not review compounded products before they are sold.
Is CJC-1295 legal in the US?
Whether a pharmacy may compound it for your prescription is what decides it. No FDA-approved drug contains CJC-1295 (with or without DAC). FDA placed it in 503A Category 2 in September 2023, citing serious adverse events including increased heart rate and systemic vasodilatory reaction, and removed it in September 2024 after the nominations were withdrawn. On December 4, 2024 the advisory committee voted against listing every form (0-13 for the free base and both DAC forms, 1-12 for the acetate). It is not on the 503A or 503B bulks list, not in any category, and not in HHS's October 2026 interim policy.
How much does CJC-1295 cost?
22 clinics publish a price. The lowest that compares per month is $150/mo at Live Vital, and the middle of 14 clinics' lowest monthly prices is about $259. What a month buys differs by clinic, so each price lists what it includes. every CJC-1295 price
What forms does CJC-1295 come in?
Clinics sell it as injection (22 prices), other (3 prices).